The National Kidney Foundation (NKF) is delighted to share an exciting update regarding its recent investment in Klinrisk, an innovative medical device company harnessing the power of artificial intelligence. With the support of the NKF's Innovation Fund, Klinrisk is committed to revolutionizing the detection and treatment of high-risk chronic kidney disease (CKD) by providing precise clinical risk prediction and invaluable decision support. This collaboration marks another significant milestone in the NKF's ongoing efforts to advance the field of kidney care.

The NKF's Innovation Fund, which aims to foster advancements in kidney health, has actively supported groundbreaking solutions that enhance health equity and improve outcomes for patients with kidney disease. Notably, the Fund has recently forged partnerships with Relavo and MediGo to drive the development of state-of-the-art technology that promotes health equity.

Klinrisk, a significant addition to the NKF's Innovation Fund portfolio, has successfully created advanced, lab-based prediction models with exceptional accuracy in early identification of high-risk CKD. These models empower healthcare professionals to intervene at the initial stages of the disease, effectively preventing the need for lifelong dialysis and revolutionizing patient outcomes.

Kevin Longino, CEO of the National Kidney Foundation said -

"My own journey as a kidney transplant recipient has shown me the urgent need for early identification and intervention in chronic kidney disease. Klinrisk's innovative use of artificial intelligence has the potential to revolutionize CKD care and improve the lives of millions of patients. By investing in Klinrisk through our Innovation Fund, we are furthering our mission to advance kidney health and ensure equitable access to life-changing innovations."

The partnership between the NKF and Klinrisk highlights their mutual dedication to advancing kidney health and promoting health equity. Through their investment in Klinrisk's pioneering technologies, the NKF's Innovation Fund strives to expedite the implementation of risk-based care models. This endeavor aims to ensure that effective interventions are deployed as early as possible, with a particular focus on underserved populations. By joining forces, the NKF and Klinrisk are working towards a future where equitable access to high-quality care for kidney health is a reality.

Navdeep Tangri, co-founder of Klinrisk said -

"My vision has always been focused on bringing risk-based care to patients with chronic kidney disease. We now have an abundance of effective therapeutics that can slow CKD progression and prevent cardiovascular events, yet they are not reaching the majority of patients until very late in the journey. Effective care for high-risk CKD starts early, and Klinrisk is committed to changing the way CKD is recognized and treated, and to eliminate kidney failure for most patients and families. Our goals are completely aligned with the NKF, making this partnership a natural fit."

With the generous support of the NKF's Innovation Fund, Klinrisk will actively enhance its predictive models and facilitate their widespread adoption within healthcare systems. The overarching objective is to enable timely interventions that effectively halt the progression of CKD, alleviating the burden of kidney failure and enhancing the quality of life for countless patients, regardless of their socio-economic circumstances.

Since its establishment in 2021, the NKF Innovation Fund has been instrumental in expediting the funding, development, and commercialization of therapies essential to kidney patients. The fund actively invests in early to mid-stage companies dedicated to pioneering innovative and patient-centric kidney treatments. Ultimately, the NKF Innovation Fund strives to achieve long-term goals such as preventing kidney disease, eradicating the transplant waitlist, and delivering superior, safer treatments for dialysis patients, enabling them to lead more fulfilling and productive lives.